Trust Signals
Key Takeaways
- Tesamorelin is the only GHRH analog currently FDA approved for adults (Egrifta SV, 2 mg subcutaneous daily for HIV-related lipodystrophy), while sermorelin's branded product was withdrawn in 2008.
- Sermorelin is a 29-amino-acid GHRH fragment; tesamorelin is the full 44-amino-acid GHRH sequence with an N-terminal trans-3-hexenoic acid modification that slows dipeptidyl peptidase IV cleavage.
- The pivotal tesamorelin Phase III trials (Falutz et al., 2007 and 2010) showed roughly 15 to 18 percent visceral adipose tissue reduction versus placebo in HIV-positive adults over 26 weeks by CT scan.
- Both peptides stimulate endogenous GH pulsatility rather than replacing GH directly, making gross IGF-1 overshoot less likely than with exogenous GH, though not impossible.
- Reconstituted solutions of both peptides are unstable at room temperature; peptide bond hydrolysis and aggregation accelerate within hours above 25 degrees Celsius, a fact most medspa protocols understate.
The Short Answer: Which Should You Choose?
For sermorelin peptide vs tesamorelin, tesamorelin carries stronger human RCT evidence and one clear approved indication. Sermorelin is lower cost and widely compounded but lacks adult RCT data. Neither is appropriate without a prescribing clinician. If visceral fat reduction in a defined population is the goal, tesamorelin's evidence wins; for general anti-aging or sleep-quality protocols, the evidence base for both is thin.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- What are sermorelin and tesamorelin structurally?
- How do they work at the receptor level?
- What does the clinical evidence actually show?
- Evidence Ledger
- What most pages get wrong about these peptides
- Formulation and stability: the gotcha nobody mentions
- Honest head-to-head: sermorelin vs tesamorelin vs exogenous GH
- Dosing and operational label literacy
- Side effects and contraindications
- FAQ
- Sources
What Are Sermorelin and Tesamorelin Structurally?
Endogenous growth hormone-releasing hormone (GHRH) is a 44-amino-acid peptide secreted from the hypothalamus. Sermorelin is the synthetic equivalent of GHRH(1-29)-NH2, the shortest N-terminal fragment that retains full receptor-binding activity at the pituitary GHRH receptor (GHRHR). Its approximate molecular weight is 3,358 Da.
Tesamorelin reproduces the full 44-amino-acid GHRH sequence and adds a trans-3-hexenoic acid group conjugated to the N-terminal tyrosine. This modification does not change receptor binding but sterically hinders cleavage by dipeptidyl peptidase IV (DPP-IV), the enzyme that degrades GHRH in plasma by cleaving the Tyr-Ala bond at positions 1 to 2. Its approximate molecular weight is 5,135 Da. The practical consequence is a longer effective half-life in plasma compared to native GHRH or sermorelin, though precise half-life figures from head-to-head pharmacokinetic studies are not widely published in accessible literature.
How Do They Work at the Receptor Level?
Both peptides bind the GHRHR, a G protein-coupled receptor on somatotroph cells of the anterior pituitary. Binding activates adenylyl cyclase, raises intracellular cyclic AMP, and triggers pulsatile GH secretion. GH then stimulates hepatic IGF-1 production, which mediates most downstream anabolic and lipolytic effects.
Because neither peptide bypasses the pituitary, somatostatin-mediated feedback still applies. This is the physiological brake that prevents GH from rising indefinitely, making GHRH analogs mechanistically self-limiting compared to exogenous recombinant GH. That said, pituitary feedback does not make overdose impossible: high-dose, chronic administration can still push IGF-1 above the reference range.
What the mechanism does NOT prove: that GH pulse amplification in a healthy adult with normal GH status produces the same body-composition outcomes seen in GH-deficient patients or in HIV lipodystrophy. Extrapolation to wellness use is speculative.
What Does the Clinical Evidence Actually Show?
Tesamorelin. The foundation is two multicenter, randomized, double-blind, placebo-controlled Phase III trials by Falutz et al., published in the New England Journal of Medicine (2007) and NEJM (2010), each enrolling several hundred HIV-positive adults with excess abdominal fat. The primary endpoint, visceral adipose tissue by CT scan, was reduced by roughly 15 to 18 percent versus placebo at 26 weeks. Triglycerides and trunk fat also improved. Glucose and HbA1c showed small adverse signals. Effects reversed after discontinuation. These trials formed the basis for FDA approval of Egrifta (later Egrifta SV) in 2010.
Smaller investigator-sponsored studies (Lo et al., published in journals including the Journal of Clinical Endocrinology and Metabolism) have examined tesamorelin in non-HIV populations, including older adults with mild cognitive impairment, with modest visceral fat and IGF-1 effects. Evidence quality is lower: smaller samples, shorter durations, and often open-label designs.
Sermorelin. Pediatric GH deficiency data supported the original Geref approval. Adult data consists largely of open-label or retrospective reports in anti-aging practice settings. A 1997 study by Walker et al. in the Journal of Clinical Endocrinology and Metabolism showed that sermorelin acetate increased GH pulse amplitude and IGF-1 in healthy elderly men, but this was a short-duration physiological study, not a body-composition endpoint trial. No large adult RCT for sermorelin exists in the published literature to this author's knowledge.
Evidence Ledger
| Claim | Best Evidence Type | Effect Direction | Confidence |
|---|---|---|---|
| Tesamorelin reduces visceral fat in HIV lipodystrophy | 2 multicenter Phase III RCTs (Falutz et al. 2007, 2010) | Reduction of roughly 15 to 18% vs placebo | High |
| Tesamorelin raises IGF-1 in adults | Human RCT (same pivotal trials) | Increase vs placebo | High |
| Sermorelin increases GH pulse amplitude in elderly | Human controlled study (Walker et al. 1997) | Increase vs baseline | Moderate |
| Sermorelin improves body composition in healthy adults | Case series, open-label clinic reports | Directionally positive, uncontrolled | Very low |
| Tesamorelin improves cognition or memory | Small RCTs in MCI populations (Lo et al.) | Modest positive signal | Low |
| Either peptide improves sleep quality | Mechanism plausibility only | Undemonstrated in controlled trials | Very low |
| GHRH analogs are safer than exogenous GH for IGF-1 excess | Mechanistic reasoning, indirect clinical data | Directionally true but not proven | Low |
What Most Pages Get Wrong About These Peptides
1. Conflating the pediatric sermorelin approval with adult evidence. Sermorelin was approved for children with GH deficiency, a documented hormonal disorder. Applying that approval as evidence for anti-aging or body-composition use in GH-sufficient adults is a logical error. The mechanism operates differently when the pituitary is already receiving normal hypothalamic input.
2. Calling tesamorelin a "fat burner." Tesamorelin's evidence is specific to HIV-associated lipodystrophy, a condition involving antiretroviral-drug-related metabolic disruption. The visceral fat reduction seen in those trials cannot be assumed to generalize to healthy individuals seeking aesthetic improvement. Extrapolation is speculation, not evidence.
3. Treating compounded peptides as equivalent to the clinical trial material. Tesamorelin used in the Falutz trials was pharmaceutical-grade material under strict GMP. Compounded versions from US 503A or 503B pharmacies vary in purity, endotoxin load, and sequence fidelity. The FDA has issued guidance restricting bulk compounding of certain peptides. Verify current regulatory status before prescribing or purchasing.
4. Ignoring the glucose signal. Both the 2007 and 2010 tesamorelin trials reported small but statistically detectable adverse effects on fasting glucose and HbA1c. For patients with prediabetes or insulin resistance, this is a meaningful clinical consideration that wellness-oriented sources routinely omit.
Formulation and Stability: The Gotcha Nobody Mentions
Both sermorelin and tesamorelin are supplied as lyophilized (freeze-dried) powder because the hydrated peptide degrades rapidly. The chemistry behind this matters.
In aqueous solution, peptide bonds are susceptible to hydrolysis, particularly at aspartyl residues and at the N-terminus. For sermorelin, the N-terminal tyrosine is vulnerable to oxidation in the presence of dissolved oxygen or light. For tesamorelin, the trans-3-hexenoic acid conjugate is more stable than native GHRH's N-terminus, but the internal peptide sequence still undergoes deamidation and aggregation over time.
Why refrigeration matters: Peptide hydrolysis and aggregation follow Arrhenius kinetics, meaning each 10 degree Celsius rise in temperature roughly doubles or more the reaction rate. A reconstituted vial left at room temperature (roughly 22 degrees Celsius) degrades meaningfully within hours to days. Refrigeration at 2 to 8 degrees Celsius slows but does not stop degradation. This is why reconstituted solutions should be used within 7 to 14 days and why freeze-thaw cycling destroys activity through aggregation.
Bacteriostatic water vs sterile water: Bacteriostatic water (with 0.9% benzyl alcohol) is recommended for multi-dose vials because benzyl alcohol slows microbial growth. However, benzyl alcohol is a mild reducing agent and can accelerate oxidation of susceptible residues at higher concentrations over time. For single-dose protocols, sterile water for injection avoids this interaction. This trade-off is rarely discussed.
Honest Head-to-Head: Sermorelin vs Tesamorelin vs Exogenous GH
| Parameter | Sermorelin | Tesamorelin | Recombinant GH (somatropin) |
|---|---|---|---|
| Regulatory status (US adults) | Compounded only, off-label | FDA approved (HIV lipodystrophy); compounded off-label otherwise | FDA approved for specific adult indications (GH deficiency, HIV wasting) |
| Mechanism | Stimulates pituitary GH release | Stimulates pituitary GH release | Directly replaces GH, bypasses pituitary |
| IGF-1 overshoot risk | Lower than GH (feedback intact) | Lower than GH (feedback intact) | Higher; requires careful dose titration |
| RCT evidence in adults | Very limited | Strong (HIV lipodystrophy) | Strong (GH deficiency, HIV wasting) |
| Typical cost (approximate) | Lower (compounded) | High (brand); moderate (compounded) | Very high |
| Visceral fat reduction evidence | Not established in RCTs | Established in HIV population | Established in GH-deficient patients |
| Where the peptide LOSES | Loses to tesamorelin on evidence quality; loses to GH on efficacy ceiling | Loses to GH on potency; evidence outside HIV is weak | Loses to GHRH analogs on side effect profile and IGF-1 safety margin |
Dosing and Operational Label Literacy
Tesamorelin (FDA-approved protocol): 2 mg subcutaneous injection once daily. The approved formulation (Egrifta SV) is a 2 mg vial reconstituted with 2.1 mL sterile water for injection, yielding 1 mg/mL. Inject into the abdomen.
Sermorelin (compounded, off-label): Common compounded concentrations range from 0.2 mg to 0.5 mg per dose, administered subcutaneously at bedtime to align with the nocturnal GH pulse. These doses are not derived from a controlled adult trial; they are extrapolated from pediatric and physiological studies. A typical compounded vial may contain 3 mg to 15 mg of lyophilized powder. Reconstitution math: if a vial contains 9 mg and you add 3 mL of bacteriostatic water, the concentration is 3 mg/mL. A 0.3 mg dose requires 0.1 mL (10 units on a U-100 insulin syringe).
Reading a COA for either peptide. Look for:
| COA Parameter | Acceptable Standard | Red Flag |
|---|---|---|
| HPLC purity | 98% or above | Below 95%, or purity method not stated |
| Molecular weight (mass spec) | Sermorelin approx. 3358 Da; tesamorelin approx. 5135 Da | No mass spec; MW not reported |
| Endotoxin (LAL test) | Below 1 EU/mg | Not tested or result not shown |
| Residual solvents | Meets USP Class 2 or Class 3 limits | Not reported |
| Sterility | Sterility test passed for injectable-grade material | Research-use-only disclaimer on injectable product |
A COA without mass spectrometry cannot confirm amino acid sequence. Sequence truncations or substitutions that preserve molecular weight are invisible to HPLC alone.
Side Effects and Contraindications
From tesamorelin's prescribing information (Egrifta SV), adverse events reported in the pivotal trials at higher rates than placebo include peripheral edema, arthralgia, and injection-site reactions, each occurring in roughly 10 to 15 percent of the treatment group. Small increases in fasting glucose and HbA1c were also detected. Tesamorelin is contraindicated in active malignancy, pregnancy, and disruption of the hypothalamic-pituitary axis (such as after pituitary surgery or cranial irradiation).
Sermorelin's side-effect data comes primarily from pediatric studies. Flushing, headache, and injection-site redness were the most common reported events. Because no large adult RCT exists, the adult adverse event rate is unknown with precision.
Both carry a theoretical concern for promoting growth in occult malignancies via IGF-1. This is a class effect of all GH-axis stimulants and a reason active cancer is a contraindication for both.
FAQ
What is the main structural difference between sermorelin and tesamorelin?
Sermorelin is a synthetic 29-amino-acid fragment of endogenous GHRH(1-44). Tesamorelin is a full 44-amino-acid GHRH analog with a trans-3-hexenoic acid group conjugated at the N-terminus, which slows enzymatic degradation and extends its effective half-life compared to sermorelin.
Which has stronger clinical evidence, sermorelin or tesamorelin?
Tesamorelin has stronger evidence. It earned FDA approval in 2010 based on two Phase III randomized controlled trials in HIV-associated lipodystrophy showing statistically significant reductions in visceral adipose tissue. Sermorelin's approval was for pediatric GH deficiency and was withdrawn for commercial reasons in 2008; adult use evidence is limited to smaller studies.
Is sermorelin FDA approved?
Sermorelin acetate was FDA approved (as Geref) for growth hormone deficiency in children. The branded product was voluntarily withdrawn from the US market in 2008 for commercial, not safety, reasons. It is currently available only through compounding pharmacies for off-label use in adults.
What dose of tesamorelin was used in the FDA-approved trials?
The pivotal Phase III trials used 2 mg subcutaneous daily. This is the approved dose for HIV-associated lipodystrophy under the brand name Egrifta SV.
Can sermorelin or tesamorelin raise IGF-1 to supraphysiologic levels?
Both stimulate GH pulsatility through the pituitary rather than replacing GH directly, so they rely on intact pituitary feedback. This self-limiting mechanism makes gross IGF-1 excess less likely than with exogenous GH, though IGF-1 monitoring is still recommended during use.
How should sermorelin and tesamorelin vials be stored?
Lyophilized powder should be stored at 2 to 8 degrees Celsius and protected from light. After reconstitution, both peptides are significantly less stable. Reconstituted solutions should be refrigerated and used within 7 to 14 days depending on the formulation; exposure to heat or repeated freeze-thaw cycles accelerates degradation.
What does tesamorelin actually do to visceral fat?
In the two Phase III trials in HIV-positive adults with excess visceral fat, tesamorelin 2 mg daily reduced visceral adipose tissue by roughly 15 to 18 percent versus placebo over 26 weeks as measured by CT scan. Effects were not maintained after discontinuation, indicating the mechanism is suppressive rather than curative.
What are the main side effects of each peptide?
Both can cause injection-site reactions, fluid retention, arthralgias, and transient blood glucose elevation. Tesamorelin's prescribing information lists edema and arthralgia in roughly 10 to 15 percent of users in trials. Sermorelin's side-effect profile from older pediatric studies includes flushing and injection-site discomfort. Neither has long-term safety data in healthy adults.
Is tesamorelin useful for body composition outside of HIV lipodystrophy?
Small investigator-sponsored studies have examined tesamorelin in non-HIV populations, including abdominal obesity and cognitive function in older adults (the Lo et al. studies). Results show modest visceral fat reduction, but evidence quality is lower than the pivotal HIV trials and no regulatory approval exists for these indications.
Can these peptides be combined with CJC-1295 or ipamorelin?
Combining a GHRH analog with a GHRP or ghrelin mimetic (like ipamorelin) is done in practice for additive GH pulse amplitude, but this is off-label, not supported by large controlled trials, and adds compounding complexity and unknown long-term risk. Sermorelin is sometimes compounded with ipamorelin; tesamorelin combinations have even less published evidence.
How do you read a certificate of analysis for these peptides?
Look for purity by HPLC of 98 percent or above, molecular weight confirmation by mass spectrometry matching the theoretical MW (sermorelin approximately 3358 Da, tesamorelin approximately 5135 Da), and absence of residual solvents and endotoxins (LAL test below 1 EU/mg). A COA without mass spec confirmation is insufficient for sequence verification.
Sources
- Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine. 2007;357(23):2359-2370.
- Falutz J, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with abdominal fat accumulation. New England Journal of Medicine. 2010;362(21):1947-1956.
- Walker RF, et al. Effects of growth hormone-releasing peptide and growth hormone-releasing hormone in aging. Journal of Clinical Endocrinology and Metabolism. 1997;(general reference to sermorelin adult GH studies in elderly).
- Lo JC, et al. Tesamorelin reduces visceral fat and improves insulin-like growth factor-1 levels in HIV-uninfected adults with abdominal fat. Open Forum Infectious Diseases. 2021.
- US Food and Drug Administration. Egrifta SV (tesamorelin) prescribing information. NDA 022505. Available at FDA.gov.
- US Food and Drug Administration. Geref (sermorelin acetate) product information. Historical NDA. FDA.gov archive.
- Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. Journal of Clinical Endocrinology and Metabolism. 2006;91(12):4792-4797. (Context for GHRH receptor biology.)
- Jette L, et al. hGRF analogs as growth hormone secretagogues: DPP-IV resistance and receptor binding. Biochemistry and Molecular Biology. 2005. (Context for trans-3-hexenoic acid stabilization strategy.)
- United States Pharmacopeia. General chapter on peptide purity and characterization standards. USP-NF online.
- FDA guidance on bulk drug substances used in compounding under section 503A/503B of the FD&C Act. FDA.gov, current edition.